Velnacrine

Velnacrine

SCHEMBL50846

Nc1c2c(nc3ccccc13)CCCC2O.O=C(O)/C=C\C(=O)O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol

The experimentally established mechanism targets of Velnacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.83
CYP1A2 P05177 1/20 0.83
CYP2C9 P11712 1/20 0.83
ALDH1A1 P00352 1/20 0.83
NR3C1 P04150 1/20 0.83
ACHE P22303 1/20 0.83
KCNH2 Q12809 1/20 0.83
TP53 P04637 1/20 0.64
HSD17B10 Q99714 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Velnacrine SCHEMBL637476 1.00 TSHR (0.83) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Velnacrine SCHEMBL7193446 1.00 TSHR (0.83) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Velnacrine SCHEMBL9634108 0.99 TSHR (0.81) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Velnacrine SCHEMBL14814443 0.96 TSHR (0.77) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Velnacrine SCHEMBL6129239 0.92 TSHR (0.69) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Velnacrine SCHEMBL194467 0.91 CYP1A2 (1.00) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Maleic Acid SCHEMBL9874286 0.85 ACHE (0.60) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Fumaric Acid SCHEMBL9874303 0.85 ACHE (0.60) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Maleic Acid SCHEMBL9875733 0.84 ACHE (0.58) TSHRCYP1A2CYP2C9ALDH1A1NR3C1
Fumaric Acid SCHEMBL9875742 0.84 ACHE (0.58) TSHRCYP1A2CYP2C9ALDH1A1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807229-B1 PROCESS FOR THE PRODUCTION OF COMPOSITE ARTICLES NOURYON CHEMICALS INT BV (NL) 2025-10-22 EP claimed
US-20250153150-A1 HETEROGENEOUS CATALYST BASED ON MOLYBDENUM OXIDE AND ITS USE IN BIOMASS TRANSFORMATION PROCESSES INSTITUTO MEXICANO DEL PETRÓLEO (MX) 2025-05-15 US claimed
WO-2025068254-A1 TREATMENT SYSTEM FOR TREATING WORKPIECES, AND METHOD FOR OPERATING SUCH A TREATMENT SYSTEM EISENMANN GMBH (DE) 2025-04-03 WO claimed
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
EP-4331094-A1 METHOD FOR OPERATING AN ELECTROMAGNETIC POWER GENERATOR FOR A WHEEL, AND POWER GENERATOR FOR A WHEEL Ronal AG (CH) 2024-03-06 EP claimed
EP-4297868-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE Hoth Therapeutics, Inc. (US) 2024-01-03 EP claimed
EP-3861039-B1 HYDROGEL COMPOSITIONS OPHTALMIC CIE (FR) 2023-11-01 EP claimed
WO-2023175159-A1 METHOD FOR OPERATING AN ELECTROMAGNETIC POWER GENERATOR FOR A WHEEL, AND POWER GENERATOR FOR A WHEEL RONAL AG (CH) 2023-09-21 WO claimed
WO-2022182658-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. (US) 2022-09-01 WO claimed
EP-3934859-A1 METHOD FOR DETERMINING A TRAJECTORY OF A ROBOT Siemens Aktiengesellschaft (DE) 2022-01-12 EP claimed
WO-1997048391-A2 METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) 1997-12-24 WO claimed
WO-1994009787-A1 SYNERGISTIC COMBINATION FOR THE THERAPY OF DEGENERATIVE AGEING DISEASES CONTAINING AN ADENOSINE ANTAGONIST AND A CHOLINOMIMETIC BOEHRINGER INGELHEIM KG (DE) 1994-05-11 WO claimed
EP-0563654-A1 Risk determination for drug treatment HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-10-06 EP claimed
EP-0479999-A1 DEVICE FOR THE NON-CONTACT MEASUREMENT OF SPEED, DISPLACEMENT DISTANCE AND/OR RANGE. TABARELLI WERNER (LI) 1992-04-15 EP claimed
EP-0465905-A1 Ceiling cladding Wilhelmi Werke GmbH & Co.KG (DE) 1992-01-15 EP claimed
WO-1991016640-A1 DEVICE FOR THE NON-CONTACT MEASUREMENT OF SPEED, DISPLACEMENT DISTANCE AND/OR RANGE TABARELLI, WERNER (LI) 1991-10-31 WO claimed
EP-0423483-A2 Procedure for determining the state of charge of an accumulator MERCEDES-BENZ AG (DE) 1991-04-24 EP claimed
EP-0349811-A1 Feed-back control system for a combustion engine ROBERT BOSCH GMBH (DE) 1990-01-10 EP claimed
EP-0237754-A1 Method to control a fuel injection apparatus, and fuel injection apparatus ROBERT BOSCH GMBH (DE) 1987-09-23 EP claimed
WO-1986004417-A1 METHOD AND DEVICE FOR THE DETERMINATION OF CHARACTERISTIC VALUES, PARTICULARLY OF GRAIN OETIKER HANS (CH) 1986-07-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250153150-A1 HETEROGENEOUS CATALYST BASED ON MOLYBDENUM OXIDE AND ITS USE IN BIOMASS TRANSFORMATION PROCESSES SQLE, FASN, SCD TSHR 4156/4885CYP1A2 190/4885CYP2C9 174/4885
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE TACR1, ACHE, TACR2 TSHR 1743/4885CYP1A2 1513/4885CYP2C9 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.